WEBULL
News
PRTA
9.38
-0.53%
-0.05
Weekly Report: what happened at PRTA last week (1208-1212)?
Weekly Report · 3d ago
Prothena Board Member Paula Cobb Resigns
TipRanks · 6d ago
Paula Cobb Steps Down from Prothena Board
Reuters · 6d ago
Prothena Announces Board of Directors Update
Barchart · 6d ago
We Think Prothena (NASDAQ:PRTA) Can Afford To Drive Business Growth
Simply Wall St · 12/11 10:14
Weekly Report: what happened at PRTA last week (1201-1205)?
Weekly Report · 12/08 10:06
H.C. Wainwright Remains a Buy on Prothena (PRTA)
TipRanks · 12/04 09:08
Prothena Highlights Advances in Protein Dysregulation Therapies for Neurodegenerative Diseases in Latest Presentation
Reuters · 12/01 21:13
Amazon To Rally Around 31%? Here Are 10 Top Analyst Forecasts For Monday
Benzinga · 12/01 14:42
Prothena Is Maintained at Market Outperform by Citizens
Dow Jones · 12/01 13:27
Prothena Price Target Raised to $19.00/Share From $11.00 by Citizens
Dow Jones · 12/01 13:27
Citizens Maintains Market Outperform on Prothena Corp, Raises Price Target to $19
Benzinga · 12/01 13:17
Prothena price target raised to $19 from $11 at Citizens JMP
TipRanks · 12/01 10:40
Weekly Report: what happened at PRTA last week (1124-1128)?
Weekly Report · 12/01 10:03
Prothena price target raised to $8 from $4 at BofA
TipRanks · 11/24 14:16
Sell Rating for Prothena Due to Reliance on Partnered Programs and Uncertainties in Phase 3 Trials
TipRanks · 11/24 11:26
Weekly Report: what happened at PRTA last week (1117-1121)?
Weekly Report · 11/24 10:07
Promising Outlook for Prothena: Buy Rating Backed by Innovative CYTOPE Platform Advancements
TipRanks · 11/20 14:25
Piper Sandler Reaffirms Their Buy Rating on Prothena (PRTA)
TipRanks · 11/20 11:37
Prothena Shareholders Approve Capital Reduction Proposal
TipRanks · 11/19 22:06
More
Webull provides a variety of real-time PRTA stock news. You can receive the latest news about Prothena through multiple platforms. This information may help you make smarter investment decisions.
About PRTA
Prothena Corporation plc is an Ireland-based late-stage clinical biotechnology company. The Company is engaged in protein dysregulation and a pipeline of investigational therapeutics for rare peripheral amyloid diseases. The Company is advancing a pipeline of therapeutic candidates for a range of indications and targets to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins. The Company’s pipeline includes both wholly owned and partnered programs being developed for the potential treatment of diseases, including AL amyloidosis, ATTR amyloidosis, Alzheimer’s disease, Parkinson’s disease and a range of other neurodegenerative diseases. Its clinical programs include birtamimab for the potential treatment of AL amyloidosis, prasinezumab for the potential treatment of Parkinson’s disease, NNC6019/PRX004 for the potential treatment of ATTR amyloidosis, and PRX005 and PRX012 for the potential treatment of Alzheimer’s disease.